Key Highlights

  • Austco Healthcare is not a household name, but the nurse-call and clinical-communications specialist has quietly built one of the more compelling small-cap
  • Reported on 28 August, FY26 Revenue rose 15.8% to a record $94.2 million, EBITDA increased 14.0% to $14.9 million, and net profit
  • The most strategically important trend is the build-up of recurring income.
  • A rising base of contracted software revenue tends to be valued more highly than one-off equipment sales because it is stickier and

Austco Healthcare is not a household name, but the nurse-call and clinical-communications specialist has quietly built one of the more compelling small-cap healthcare stories on the ASX. The company designs and installs the systems that let patients call for help and that route clinical alerts to the right staff in hospitals and aged-care facilities, and it increasingly layers recurring software revenue on top of that hardware base. Its FY26 result showed both record revenue and accelerating profitability, sharpening the case for a closer look.

Reported on 28 August, FY26 revenue rose 15.8% to a record $94.2 million, EBITDA increased 14.0% to $14.9 million, and net profit after tax jumped 51.8% to $9.0 million. Gross Margin improved 140 basis points to 53.4%, a sign that the mix is shifting toward higher-value software and services. The company held $16.3 million in cash with no material borrowings and generated $12.5 million of operating cash during the year, though the board again Retained Earnings rather than paying a dividend, choosing to reinvest for growth.

Recurring revenue is the quiet engine

The most strategically important trend is the build-up of recurring income. Software and software-maintenance-agreement revenue grew 19% to $11.4 million, underpinned by agreements that typically run one to five years. Austco says it now supports more than 5,000 healthcare facilities across over 60 countries, a large installed base that creates a natural pipeline for maintenance renewals, upgrades and add-on software. Equipment revenue rose 12.1% to $51.9 million and installation revenue climbed 21.4% to $31.0 million, showing the core hardware Business is still growing while the recurring layer expands on top.

A rising base of contracted software revenue tends to be valued more highly than one-off equipment sales because it is stickier and more predictable, so the mix shift is central to the Investment thesis.

The United States is the growth frontier

Much of Austco's opportunity lies in North America, where its Pulse Mobile clinical-communications offering has been gaining traction across US hospitals. Expansion in that large market, alongside integrated reseller acquisitions, is the primary driver management has pointed to for continued growth. The company also carried a healthy order book, with unfilled contracted revenue of $51.2 million at year-end, up 13%, and highlighted recent wins including a $1.85 million retrofit project in Brazil and a $1.1 million nurse-call contract in Victoria.

Catalysts and risks

Into FY27, the catalysts to watch are continued US rollout and Pulse Mobile adoption, further growth in recurring software revenue, conversion of the order book into revenue, and any bolt-on reseller acquisitions that widen distribution. Management struck an upbeat tone on the pipeline and cost benefits, so evidence that margins keep expanding would reinforce the story.

The risks are those of a small-cap in a specialised niche. Equipment and installation revenue can be lumpy and tied to hospital and aged-care Capital budgets, which are sensitive to funding cycles. Austco competes against larger clinical-communications players, faces currency exposure through its international footprint, and depends on successful integration of acquisitions. The decision to withhold a dividend, while sensible for reinvestment, removes near-term income appeal.

Austco Healthcare enters FY27 with record revenue, a 52% lift in net profit, a growing recurring-revenue base and a solid order book, funded by a clean, debt-light balance sheet. For investors hunting under-the-radar healthcare exposure, it is a genuinely interesting story, provided the US expansion and software momentum continue to convert into the profit growth the FY26 result delivered.